Clinical Trial Update: QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations) [Phase 3]

View source ↗

Summary

This Phase 3 trial compared indacaterol/glycopyrronium (QVA) to salmeterol/fluticasone (Advair) over 52 weeks in COPD and reported results on exacerbations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QVA (indacaterol/glycopyrronium)
• Salmeterol/Fluticasone (fluticasone propionate/salmeterol)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2016-05-16